Search
Pidacmeran
go.drugbank.com/drugs/DB16401InvestigationalPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Geptanolimab
go.drugbank.com/drugs/DB16417InvestigationalGeptanolimab is under investigation in clinical trial NCT03502629 (Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)).
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]
Synonyms: SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)GRAd-COV2
go.drugbank.com/drugs/DB16428InvestigationalThis therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423]. … GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalSponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588]. … is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad T-cell
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
APL-9
go.drugbank.com/drugs/DB16460InvestigationalIt shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is designed for intravenous administration for acute use
DFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...
Synonyms: BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL-, N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDECategories: Heterocyclic Compounds, 1-Ring